AAAAI MEETING: Roche's lebrikizumab cuts asthma attacks in periostin-high patients
This article was originally published in Scrip
Executive Summary
The effect of Roche's lebrikizumab on asthma attacks in severe asthmatics who expressed high levels of the protein periostin may have been "unprecedented" in two Phase IIb clinical trials, but ongoing Phase III studies will have to confirm the improved rate of exacerbations due to inconsistent dosing periods in the Phase IIb LUTE and VERSE studies.